Inhibition of core fucosylation limits progression of diabetic kidney disease

被引:13
作者
Fang, Ming [1 ,2 ]
Kang, Le [3 ]
Wang, Xiaolang [4 ]
Guo, Xianan [2 ]
Wang, Weidong [2 ]
Qin, Biaojie [2 ]
Du, Xiangning [2 ]
Tang, Qingzhu [2 ]
Lin, Hongli [1 ,2 ]
机构
[1] Dalian Med Univ, Grad Sch, 9 Western Sect,Lvshun South St, Dalian 116044, Peoples R China
[2] Dalian Med Univ, Ctr Kidney Dis Translat Med Liaoning Prov, Dept Nephrol, Affiliated Hosp 1, Dalian 116011, Peoples R China
[3] Dalian Univ, Dept Physiol & Pathophysiol, Med Coll, 10 Xuefu Rd, Dalian 116622, Peoples R China
[4] Dalian Med Univ, Ctr Kidney Dis Translat Med Liaoning Prov, Dept Pediat, Affiliated Hosp 1, Dalian 116011, Peoples R China
基金
美国国家科学基金会;
关键词
FUT8; Core fucosylation; Diabetic kidney disease; Podocyte; GROWTH-FACTOR-BETA; ACTIVATION; ANTIBODY; NEPHROPATHY; MECHANISMS; EXPRESSION; PHENOTYPE; RECEPTOR;
D O I
10.1016/j.bbrc.2019.10.037
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: FUT8-mediated core fucosylation, which transfers a fucose residue from GDP-fucose to core-GIcNAc of the N-linked type glycoproteins, is crucial for signaling receptors function. Core fucosylation is involved in various biological processes such as cell proliferation, apoptosis, differentiation and immune regulation. Our previous studies demonstrated that inhibiting core fucosylation prevented renal interstitial fibrosis of UUO murine models, but its role in the development of diabetic kidney disease (DKD) remains unclear. This study aimed to clarify the protective effects and molecular mechanisms during the progress of DKD by inhibiting core fucosylation in vivo. Methods: Core fucosylation was examined in streptozotocin (STZ)-induced diabetic mouse model. Then a new Fut8 mutation mouse model in which exon 7 of Fut8 gene is deleted was constructed for diabetes induction. Metabolic and renal parameters were measured. Renal structure, fibrosis, and podocyte injury were assessed, and underlying mechanisms were investigated. Results: The levels of fasting blood glucose, glycated hemoglobin, kidney-weight-to- body-weight (KW/ BW) and urine albumin-to-creatinine (ACR) were increased at 16 weeks post injection. KW/BW and urine ACR were decreased significantly by inhibiting core fucosylation. The renal pathology, fibrosis, and podocyte injury were mitigated significantly by inhibiting core fucosylation. The protective effects of inhibiting core fucosylation were mediated by downregulated of the phosphorylation of Smad2/3 and extracellular signal-regulated kinase (ERK). Conclusions: Our results indicate that FUT8-based treatment might be a promising intervention strategy in therapeutic paradigm of DKD. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:612 / 618
页数:7
相关论文
共 25 条
[1]   The potential of N-glycosylation profiles as biomarkers for monitoring the progression of Type II diabetes mellitus towards diabetic kidney disease [J].
Adua E. ;
Anto E.O. ;
Roberts P. ;
Kantanka O.S. ;
Aboagye E. ;
Wang W. .
Journal of Diabetes & Metabolic Disorders, 2018, 17 (2) :233-246
[2]   Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat [J].
Benigni, A ;
Zoja, C ;
Corna, D ;
Zatelli, C ;
Conti, S ;
Campana, M ;
Gagliardini, E ;
Rottoli, D ;
Zanchi, C ;
Abbate, M ;
Ledbetter, S ;
Remuzzi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1816-1824
[3]   N-Glycan Profile and Kidney Disease in Type 1 Diabetes [J].
Bermingham, Mairead L. ;
Colombo, Marco ;
McGurnaghan, Stuart J. ;
Blackbourn, Luke A. K. ;
Vuckovic, Frano ;
Bakovic, Maja Pucic ;
Trbojevic-Akmacic, Irena ;
Lauc, Gordan ;
Agakov, Felix ;
Agakova, Anna S. ;
Hayward, Caroline ;
Klaric, Lucija ;
Palmer, Colin N. A. ;
Petrie, John R. ;
Chalmers, John ;
Collier, Andrew ;
Green, Fiona ;
Lindsay, Robert S. ;
Macrury, Sandra ;
McKnight, John A. ;
Patrick, Alan W. ;
Thekkepat, Sandeep ;
Gornik, Olga ;
McKeigue, Paul M. ;
Colhoun, Helen M. .
DIABETES CARE, 2018, 41 (01) :79-87
[4]   Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in dbldb mice [J].
Chen, S ;
Igleasias-de la Cruz, MC ;
Jim, B ;
Hong, SW ;
Isono, M ;
Ziyadeh, FN .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 300 (01) :16-22
[5]   Cellular and molecular mechanisms in kidney fibrosis [J].
Duffield, Jeremy S. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (06) :2299-2306
[6]   Long-term exposure of proximal tubular epithelial cells to glucose induces transforming growth factor-β1 synthesis via an autocrine PDGF loop [J].
Fraser, D ;
Brunskill, N ;
Ito, T ;
Phillips, A .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (06) :2565-2574
[7]   RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis [J].
Hagiwara, Shinji ;
Sourris, Karly ;
Ziemann, Mark ;
Wu Tieqiao ;
Mohan, Muthukumar ;
McClelland, Aaron D. ;
Brennan, Eoin ;
Forbes, Josephine ;
Coughlan, Melinda ;
Harcourt, Brooke ;
Penfold, Sally ;
Wang, Bo ;
Higgins, Gavin ;
Pickering, Raelene ;
El-Osta, Assam ;
Thomas, Merlin C. ;
Cooper, Mark E. ;
Kantharidis, Phillip .
DIABETES, 2018, 67 (05) :960-973
[8]   Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes [J].
Keser, Toma ;
Gornik, Ivan ;
Vuckovic, Frano ;
Selak, Najda ;
Pavic, Tamara ;
Lukic, Edita ;
Gudelj, Ivan ;
Gasparovic, Hrvoje ;
Biocina, Bojan ;
Tilin, Therese ;
Wennerstrom, Annika ;
Mannisto, Satu ;
Salomaa, Veikko ;
Havulinna, Aki ;
Wang, Wei ;
Wilson, James F. ;
Charutvedi, Nishi ;
Perola, Markus ;
Campbell, Harry ;
Lauc, Gordan ;
Gornik, Olga .
DIABETOLOGIA, 2017, 60 (12) :2352-2360
[9]   Over-expression of platelet-derived growth factor in human diabetic nephropathy [J].
Langham, RG ;
Kelly, DJ ;
Maguire, J ;
Dowling, JP ;
Gilbert, RE ;
Thomson, NM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (07) :1392-1396
[10]   Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice [J].
Lassila, M ;
Jandeleit-Dahm, K ;
Seah, KK ;
Smith, CM ;
Calkin, AC ;
Allen, TJ ;
Cooper, ME .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :363-373